Investors Sue Biopharma Co. After Clinical Trial Data Toss

By Emilie Ruscoe · January 22, 2024, 9:30 PM EST

Biopharmaceutical company BioVie and three of its executives are facing an investors' proposed class action after "suspected coordinated improprieties" led the company to toss data for over 80% of the subjects...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

IN RE BIOVIE INC. SECURITIES LITIGATION

Case Number

Court

Nevada

Nature of Suit

Securities/Commodities

Date Filed

January 19, 2024

Recent Articles By Emilie

May 14, 2024
Vein Tech Maker Faces Investor Suit Over DOJ Kickback Probe
April 19, 2024
AI Health Data Co. Faces Investor Suit Over Accounting Issues
April 18, 2024
Doximity Faces Investor Suit Over Slashed Revenue Hopes
March 15, 2024
'Cobra Venom' Painkiller Co. Inks Deal To Settle SEC Claims
February 21, 2024
Former Exec Convicted Of Medtronic Insider Trading Scheme
February 12, 2024
Investors Win Class Cert. Against Failed COVID Test Maker
December 19, 2023
Acadia Investor Says Officers Overhyped Drug's Prospects
December 06, 2023
Cancer Test Co. Overpromised Insurer Coverage, Suit Says
November 27, 2023
Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit
October 03, 2023
Pomerantz Plucks $5.5M Fee For Clover Health Investor Deal